Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2008-06-09
2009-12-22
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S192100, C514S002600, C530S350000, C536S023400
Reexamination Certificate
active
07635474
ABSTRACT:
Nucleic acid molecules encoding fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells.
REFERENCES:
patent: 5851999 (1998-12-01), Ullrich et al.
patent: 6011003 (2000-01-01), Charnock-Jones et al.
patent: 6100071 (2000-08-01), Davis-Smyth et al.
patent: 6270993 (2001-08-01), Shibuya et al.
patent: 6897294 (2005-05-01), Davis-Smyth et al.
patent: 2005/0281831 (2005-12-01), Davis-Smyth et al.
patent: WO97/44453 (1997-11-01), None
patent: WO 98/13071 (1998-04-01), None
patent: WO 00/75319 (2000-12-01), None
Holash et al., 2002, “VEGF-Trap: a VEGF blocker with potent antitumor effects.” PNAS Aug. 20;99(17):11393-8.
Heidran et al., 1990, “Chimeric alpha- and beta-platelet-derived growth factor (PDGF) receptors define three immunoglobulin-like domains of the alpha-PDGF receptor that determine PDGF-AA binding specificity.” J Biol Chem. Nov. 5;265(31):18741-4.
Cunningham et al., 1997, “Identification of the extracellular domains of Flt-1 that mediate ligand interactions.” Biochem Biophys Res Commun. Feb. 24;231(3):596-9.
Fuh et al., “Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor.” J Biol Chem. May 1;273(18):11197-204. ( 1998 ).
Wiesman et al., 1997, “Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.” Cell. Nov. 28;91(5):695-704.
Barleon et al., 1997, “Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1.” J Biol Chem. Apr. 18;272(16):10382-8.
Davis-Smyth et al., 1998, “Mapping the charged residues in the second immunoglobulin-like domain of the vascular endothelial growth factor/placenta growth factor receptor Flt-1 required for binding and structural stability.” J Biol Chem. Feb. 6;273(6):3216-22.
Wulff et al., 2002, “Prevention of thecal angiogenesis, antral follicular growth, and ovulation in the primate by treatment with vascular endothelial growth factor Trap R1R2.” Endocrinology. Jul.;143(7):2797-807.
Davis-Smyth et al., 1996, “The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.” EMBO J. Sep. 16;15(18):4919-27.
Palu et al., 1999, “In pursuit of new developments for gene therapy of human diseases.” J Biotechnol. Feb. 5;68 (1):1-13.
Wang et al., 1999, “Rapid analysis of gene expression (RAGE) facilitates universal expression profiling.” Nucleic Acids Res. Dec. 1;27(23):4609-18.
Kaufman et al., 1999, Transgenic analysis of a 100-kb human B-globin cluster-containing DNA fragment propagated as a bacterial artificial chromosome. Blood 94(9): 3178-3184.
Wigley et al., 1994, “Site-specific transgene insertion: an approach.” Reprod. Fertil. Dev. 6:585-588.
Wells, 1990, “Additivity of mutational effects in proteins.” Biochemistry 29(37): 8509-8517.
Ngo et al., 1994, “Computational complexity, protein structure prediction, and the Levinthal paradox. In Merz and Le Grand (Eds.) The Protein Folding Problem and Tertiary Structure Prediction.” Birkhauser: Boston, pp. 491-495.
Skolnick et al., 2000, “From genes to protein structure and function: novel applications of computational approaches in the genomic era.” Trends in Biotechnology 18:34-39.
Phillips, 2001, “The challenge of gene therarpy and DNA delivery.” Journal of Pharmacy and Pharmacology 53:1169-1174.
Daly Thomas J.
Fandl James P.
Papadopoulos Nicholas J.
Gregg, Esq. Valeta
Lockard Jon M
Regeneron Pharmaceuticals Inc.
Saoud Christine J
LandOfFree
VEGF-binding fusion proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with VEGF-binding fusion proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and VEGF-binding fusion proteins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4085484